CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.
Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)自然杀伤(NK)细胞疗法代表了癌症免疫治疗的一个新兴前沿。CAR-NK 细胞提供了“现货型”治疗的潜力,并具有有利的安全性特征,部分原因在于其固有的 HLA 非限制性肿瘤靶向能力以及不引起移植物抗宿主病。使用脐带血来源 CAR-NK 细胞的里程碑式临床研究以及另一项使用 iPSC 来源 CAR-NK 细胞的研究,已报告了令人瞩目的缓解率、持久缓解和极小的毒性。此外,越来越多的正在进行的临床试验正在探索创新策略,以增强持久性、克服实体瘤挑战并防止抗原逃逸。这些进展共同凸显了 CAR-NK 疗法革新癌症治疗的潜力,同时解决了当前 CAR-T 细胞方法相关的局限性。
Chimeric antigen receptor (CAR) natural killer (NK) cell therapy represents an emerging frontier in cancer immunotherapy. CAR-NK cells offer the potential for "off-the-shelf" treatments with a favorable safety profile, due in part to their innate capacity for HLA-unrestricted tumor targeting and an absence of graft-versus-host disease. Landmark clinical studies using cord blood - derived CAR-NK cells and another employing iPSC-derived CAR-NK cells have reported impressive response rates, durable remissions, and minimal toxicity.
Furthermore, a growing landscape of ongoing clinical trials is exploring innovative strategies to enhance persistence, overcome solid tumor challenges, and prevent antigen escape. These advances collectively underscore the potential of CAR-NK therapies to revolutionize cancer treatment while addressing limitations associated with current CAR-T cell approaches.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。